{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:53:46Z","timestamp":1776905626795,"version":"3.51.2"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"DOI":"10.1186\/s12882-026-04848-7","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:55:04Z","timestamp":1773665704000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of supportive and immunosuppressive therapies in the treatment of lgA nephropathy: a network Meta-analysis of randomized clinical trials"],"prefix":"10.1186","volume":"27","author":[{"given":"Xintong","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yangyang","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huaijue","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisen","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"issue":"25","key":"4848_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314. https:\/\/doi.org\/10.1056\/NEJMra1206793.","journal-title":"N Engl J Med"},{"key":"4848_CR2","doi-asserted-by":"publisher","unstructured":"Magistroni R, D\u2019Agati VD, Appel GB, et al. New developments in the genetics, pathogenesis, and therapy of IgA nephropathy. kidney Int. 2015;88(5):974\u201389. https:\/\/doi.org\/10.1038\/ki.2015.252.","DOI":"10.1038\/ki.2015.252"},{"issue":"8","key":"4848_CR3","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nrneph.2014.92","volume":"10","author":"IS Roberts","year":"2014","unstructured":"Roberts IS. Pathology of IgA nephropathy. Nat Rev Nephrol. 2014;10(8):445\u201354. https:\/\/doi.org\/10.1038\/nrneph.2014.92.","journal-title":"Nat Rev Nephrol"},{"key":"4848_CR4","doi-asserted-by":"publisher","unstructured":"Barratt J, Feehally J. Treatment of IgA nephropathy. kidney Int. 2006;69(11):1934\u201338. https:\/\/doi.org\/10.1038\/sj.ki.5000419.","DOI":"10.1038\/sj.ki.5000419"},{"issue":"1","key":"4848_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","volume":"21","author":"CK Cheung","year":"2025","unstructured":"Cheung CK, Alexander S, Reich HN, et al. The pathogenesis of IgA nephropathy and implications for treatment. Nat Rev Nephrol. 2025;21(1):9\u201323. https:\/\/doi.org\/10.1038\/s41581-024-00885-3.","journal-title":"Nat Rev Nephrol"},{"issue":"5","key":"4848_CR6","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s40265-024-02036-1","volume":"84","author":"L Del Vecchio","year":"2024","unstructured":"Del Vecchio L, Allinovi M, Comolli S, et al. Drugs in development to treat IgA nephropathy. Drugs. 2024;84(5):503\u201325. https:\/\/doi.org\/10.1007\/s40265-024-02036-1.","journal-title":"Drugs"},{"key":"4848_CR7","doi-asserted-by":"publisher","unstructured":"Fellstr\u00f6m BC, Barratt J, Cook H, et al. Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial. Lancet (London, England. 2017;389(10084):2117-2127 https:\/\/doi.org\/10.1016\/S0140-6736(17)30550-0.","DOI":"10.1016\/S0140-6736(17)30550-0"},{"issue":"10405","key":"4848_CR8","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/s0140-6736(23)01554-4","volume":"402","author":"R Lafayette","year":"2023","unstructured":"Lafayette R, Kristensen J, Stone A, et al. Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgard): 2-year results from a randomised phase 3 trial. Lancet. 2023;402(10405):859\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(23)01554-4.","journal-title":"Lancet"},{"issue":"10417","key":"4848_CR9","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/s0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390. https:\/\/doi.org\/10.1016\/s0140-6736(23)02302-4.","journal-title":"Lancet"},{"key":"4848_CR10","doi-asserted-by":"publisher","unstructured":"Heerspink HJL, Jardine M, Kohan DE, et al. Atrasentan in patients with IgA nephropathy. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2409415.","DOI":"10.1056\/NEJMoa2409415"},{"issue":"3","key":"4848_CR11","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/cjn.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, L AI, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381. https:\/\/doi.org\/10.2215\/cjn.08600718.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"19","key":"4848_CR12","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1001\/jama.2022.5368","volume":"327","author":"J Lv","year":"2022","unstructured":"Lv J, Wong MG, Hladunewich MA, et al. Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2022;327(19):1888\u201398. https:\/\/doi.org\/10.1001\/jama.2022.5368.","journal-title":"JAMA"},{"issue":"5","key":"4848_CR13","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1111\/j.1523-1755.2004.00588.x","volume":"65","author":"BD Maes","year":"2004","unstructured":"Maes BD, Oyen R, Claes K, et al. Mycophenolate mofetil in IgA nephropathy: results of a 3-year prospective placebo-controlled randomized study. Kidney Int. 2004;65(5):1842\u201349. https:\/\/doi.org\/10.1111\/j.1523-1755.2004.00588.x.","journal-title":"Kidney Int"},{"issue":"10","key":"4848_CR14","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial. Nephrol Dial Transpl. 2005;20(10):2139\u201345. https:\/\/doi.org\/10.1093\/ndt\/gfh974.","journal-title":"Nephrol Dial Transpl"},{"issue":"2","key":"4848_CR15","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1111\/j.1523-1755.2005.00460.x","volume":"68","author":"S Tang","year":"2005","unstructured":"Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy. Kidney Int. 2005;68(2):802\u201312. https:\/\/doi.org\/10.1111\/j.1523-1755.2005.00460.x.","journal-title":"Kidney Int"},{"key":"4848_CR16","doi-asserted-by":"publisher","unstructured":"Tang SC, Tang AW, Wong SS, et al. Long-term study of mycophenolate mofetil treatment in IgA nephropathy. Kidney Int. 2010;77(6):543-549. https:\/\/doi.org\/10.1038\/ki.2009.499.","DOI":"10.1038\/ki.2009.499"},{"issue":"6","key":"4848_CR17","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","volume":"69","author":"JH Hou","year":"2017","unstructured":"Hou JH, Le WB, Chen N, et al. Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial. Am J Kidney Dis. 2017;69(6):788\u201395. https:\/\/doi.org\/10.1053\/j.ajkd.2016.11.027.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"4848_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1053\/j.ajkd.2015.06.013","volume":"66","author":"RJ Hogg","year":"2015","unstructured":"Hogg RJ, Bay RC, Jennette JC, et al. Randomized controlled trial of mycophenolate mofetil in children, adolescents, and adults with IgA nephropathy. Am J Kidney Dis. 2015;66(5):783\u201391. https:\/\/doi.org\/10.1053\/j.ajkd.2015.06.013.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"4848_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.5414\/CP201887","volume":"52","author":"X Liu","year":"2014","unstructured":"Liu X, Dewei D, Sun S, et al. Treatment of severe IgA nephropathy: mycophenolate mofetil\/prednisone compared to cyclophosphamide\/prednisone. Int J Clin Pharmacol Ther. 2014;52(2):95\u2013102. https:\/\/doi.org\/10.5414\/CP201887.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"4848_CR20","doi-asserted-by":"publisher","unstructured":"Han SY, Jung CY, Lee SH, et al. A multicenter, randomized, open-label, comparative, phase IV study to evaluate the efficacy and safety of combined treatment with mycophenolate mofetil and corticosteroids in advanced immunoglobulin a nephropathy. kidney Res Clin Pract. 2022;41(4):452\u201361. https:\/\/doi.org\/10.23876\/j.krcp.21.146","DOI":"10.23876\/j.krcp.21.146"},{"key":"4848_CR21","doi-asserted-by":"publisher","unstructured":"Hou FF, Xie D, Wang J, et al. Effectiveness of mycophenolate mofetil among patients with progressive IgA nephropathy: a randomized clinical trial. JAMA Netw Open. 2023;6(2):e2254054. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.54054.","DOI":"10.1001\/jamanetworkopen.2022.54054"},{"key":"4848_CR22","doi-asserted-by":"publisher","unstructured":"Kim YC, Chin HJ, Koo HS, et al. Tacrolimus decreases albuminuria in patients with IgA nephropathy and normal blood pressure: a double-blind randomized controlled trial of efficacy of tacrolimus on IgA nephropathy. PLoS One. 2013;8(8):e71545. https:\/\/doi.org\/10.1371\/journal.pone.0071545.","DOI":"10.1371\/journal.pone.0071545"},{"issue":"10","key":"4848_CR23","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi C, Andrulli S, Pani A, et al. Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J Am Soc Nephrol. 2010;21(10):1783\u201390. https:\/\/doi.org\/10.1681\/ASN.2010010117.","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"4848_CR24","doi-asserted-by":"publisher","first-page":"511","DOI":"10.2215\/CJN.01120905","volume":"1","author":"N Yoshikawa","year":"2006","unstructured":"Yoshikawa N, Honda M, Iijima K, et al. Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial. Clin J Am Soc Nephrol. 2006;1(3):511\u201317. https:\/\/doi.org\/10.2215\/CJN.01120905.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4848_CR25","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.2215\/cjn.08630910","volume":"6","author":"K Kamei","year":"2011","unstructured":"Kamei K, Nakanishi K, Ito S, et al. Long-term results of a randomized controlled trial in childhood IgA nephropathy. Clin J Am Soc Nephrol. 2011;6(6):1301\u201307. https:\/\/doi.org\/10.2215\/cjn.08630910.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"4848_CR26","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/ASN.2017060713","volume":"29","author":"T Rauen","year":"2018","unstructured":"Rauen T, Fitzner C, Eitner F, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317\u201325. https:\/\/doi.org\/10.1681\/ASN.2017060713.","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"4848_CR27","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1681\/asn.V131142","volume":"13","author":"FW Ballardie","year":"2002","unstructured":"Ballardie FW, Roberts ISD. Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy. J Am Soc Nephrol. 2002;13(1):142\u201348. https:\/\/doi.org\/10.1681\/asn.V131142.","journal-title":"J Am Soc Nephrol"},{"key":"4848_CR28","doi-asserted-by":"publisher","unstructured":"Liu LJ, Yang YZ, Shi SF, et al. Effects of Hydroxychloroquine on proteinuria in IgA nephropathy: a randomized controlled trial. Am J Kidney Dis. 2019;74(1):15-22. https:\/\/doi.org\/10.1053\/j.ajkd.2019.01.026.","DOI":"10.1053\/j.ajkd.2019.01.026"},{"issue":"7","key":"4848_CR29","doi-asserted-by":"publisher","first-page":"675","DOI":"10.2169\/internalmedicine.53.1136","volume":"53","author":"H Liu","year":"2014","unstructured":"Liu H, Xu X, Fang Y, et al. Comparison of glucocorticoids alone and combined with cyclosporine a in patients with IgA nephropathy: a prospective randomized controlled trial. Intern Med. 2014;53(7):675\u201381. https:\/\/doi.org\/10.2169\/internalmedicine.53.1136.","journal-title":"Intern Med"},{"issue":"8","key":"4848_CR30","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/j.kjms.2014.04.002","volume":"30","author":"L Xu","year":"2014","unstructured":"Xu L, Liu ZC, Guan GJ, et al. Cyclosporine a combined with medium\/low dose prednisone in progressive IgA nephropathy. The Kaohsiung J Med Sci. 2014;30(8):390\u201395. https:\/\/doi.org\/10.1016\/j.kjms.2014.04.002.","journal-title":"The Kaohsiung J Med Sci"},{"issue":"2","key":"4848_CR31","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/j.1440-1797.2006.00547.x","volume":"11","author":"T Lou","year":"2006","unstructured":"Lou T, Wang C, Chen Z, et al. Randomised controlled trial of leflunomide in the treatment of immunoglobulin a nephropathy. Nephrol (Carlton). 2006;11(2):113\u201316. https:\/\/doi.org\/10.1111\/j.1440-1797.2006.00547.x.","journal-title":"Nephrol (Carlton)"},{"key":"4848_CR32","doi-asserted-by":"publisher","unstructured":"Cheng G, Liu D, Margetts P, et al. Valsartan combined with clopidogrel and\/or leflunomide for the treatment of progressive immunoglobulin a nephropathy. Nephrology (Carlton). 2015;20(2):77\u201384. https:\/\/doi.org\/10.1111\/nep.12359.","DOI":"10.1111\/nep.12359"},{"issue":"16","key":"4848_CR33","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.4103\/0366-6999.187848","volume":"129","author":"J Wu","year":"2016","unstructured":"Wu J, Duan SW, Sun XF, et al. Efficacy of leflunomide, Telmisartan, and clopidogrel for immunoglobulin a nephropathy: a randomized controlled trial. Chin Med J (Engl). 2016;129(16):1894\u2013903. https:\/\/doi.org\/10.4103\/0366-6999.187848.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"4848_CR34","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/0886022X.2021.1963775","volume":"43","author":"Z Ni","year":"2021","unstructured":"Ni Z, Zhang Z, Yu Z, et al. Leflunomide plus low-dose prednisone in patients with progressive IgA nephropathy: a multicenter, prospective, randomized, open-labeled, and controlled trial. Ren Fail. 2021;43(1):1214\u201321. https:\/\/doi.org\/10.1080\/0886022X.2021.1963775.","journal-title":"Ren Fail"},{"issue":"29","key":"4848_CR35","doi-asserted-by":"publisher","first-page":"48375","DOI":"10.18632\/oncotarget.16468","volume":"8","author":"L Min","year":"2017","unstructured":"Min L, Wang Q, Cao L, et al. Comparison of combined leflunomide and low-dose corticosteroid therapy with full-dose corticosteroid monotherapy for progressive IgA nephropathy. Oncotarget. 2017;8(29):48375\u201384. https:\/\/doi.org\/10.18632\/oncotarget.16468.","journal-title":"Oncotarget"},{"key":"4848_CR36","first-page":"198","volume-title":"Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial","author":"BA Julian","year":"1993","unstructured":"Julian BA, Barker C. Alternate-day prednisone therapy in IgA nephropathy. Preliminary analysis of a prospective, randomized, controlled trial. Vol. 104. Contrib Nephrol; 1993. p. 198\u2013206."},{"issue":"5","key":"4848_CR37","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1016\/s0272-6386(03)00194-x","volume":"41","author":"R Katafuchi","year":"2003","unstructured":"Katafuchi R, Ikeda K, Mizumasa T, et al. Controlled, prospective trial of steroid treatment in IgA nephropathy: a limitation of low-dose prednisolone therapy. Am J Kidney Dis. 2003;41(5):972\u201383. https:\/\/doi.org\/10.1016\/s0272-6386(03)00194-x.","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"4848_CR38","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.asn.0000103869.08096.4f","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157\u201363. https:\/\/doi.org\/10.1097\/01.asn.0000103869.08096.4f.","journal-title":"J Am Soc Nephrol"},{"issue":"12","key":"4848_CR39","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, et al. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transpl. 2009;24(12):3694\u2013701. https:\/\/doi.org\/10.1093\/ndt\/gfp356.","journal-title":"Nephrol Dial Transpl"},{"issue":"5","key":"4848_CR40","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial. JAMA. 2017;318(5):432\u201342. https:\/\/doi.org\/10.1001\/jama.2017.9362.","journal-title":"JAMA"},{"issue":"1","key":"4848_CR41","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324. https:\/\/doi.org\/10.1016\/j.kint.2021.03.033.","journal-title":"Kidney Int"},{"issue":"3","key":"4848_CR42","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1016\/j.ekir.2022.12.014","volume":"8","author":"J Lv","year":"2023","unstructured":"Lv J, Liu L, Hao C, et al. Randomized phase 2 trial of telitacicept in patients with IgA nephropathy with persistent proteinuria. Kidney Int Rep. 2023;8(3):499\u2013506. https:\/\/doi.org\/10.1016\/j.ekir.2022.12.014.","journal-title":"Kidney Int Rep"},{"issue":"6","key":"4848_CR43","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1016\/j.kint.2024.03.012","volume":"105","author":"R Lafayette","year":"2024","unstructured":"Lafayette R, Barbour S, Israni R, et al. A phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy. Kidney Int. 2024;105(6):1306\u201315. https:\/\/doi.org\/10.1016\/j.kint.2024.03.012.","journal-title":"Kidney Int"},{"issue":"1","key":"4848_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa2305635","volume":"390","author":"M Mathur","year":"2024","unstructured":"Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of Sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390(1):20\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2305635.","journal-title":"N Engl J Med"},{"key":"4848_CR45","doi-asserted-by":"publisher","unstructured":"Nikolakopoulou A, Higgins JPT, Papakonstantinou T, et al. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med. 2020;17(4):e1003082. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","DOI":"10.1371\/journal.pmed.1003082"},{"issue":"6","key":"4848_CR46","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/cjn.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338. https:\/\/doi.org\/10.2215\/cjn.0000000000000135.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"4848_CR47","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1093\/ndt\/gfae252","volume":"40","author":"X Shen","year":"2024","unstructured":"Shen X, Chen P, Liu M, et al. Long-term outcomes of IgA nephropathy in China. Nephrol Dial Transpl. 2024;40(6):1137\u201346. https:\/\/doi.org\/10.1093\/ndt\/gfae252.","journal-title":"Nephrol Dial Transpl"},{"key":"4848_CR48","doi-asserted-by":"publisher","unstructured":"Liu T, Wang Y, Mao H, et al. Efficacy and safety of immunosuppressive therapies in the treatment of high-risk IgA nephropathy: a network meta-analysis. Med (Baltim). 2021;100(8):e24541. https:\/\/doi.org\/10.1097\/md.0000000000024541.","DOI":"10.1097\/md.0000000000024541"},{"issue":"1","key":"4848_CR49","doi-asserted-by":"publisher","first-page":"6062","DOI":"10.1038\/s41598-020-63170-w","volume":"10","author":"J Tan","year":"2020","unstructured":"Tan J, Dong L, Ye D, et al. The efficacy and safety of immunosuppressive therapies in the treatment of IgA nephropathy: a network meta-analysis. Sci Rep. 2020;10(1):6062. https:\/\/doi.org\/10.1038\/s41598-020-63170-w.","journal-title":"Sci Rep"},{"issue":"30","key":"4848_CR50","doi-asserted-by":"publisher","first-page":"2400","DOI":"10.2174\/0113816128304327240620093048","volume":"30","author":"Z Chen","year":"2024","unstructured":"Chen Z, Chen W, Zheng L, et al. Treatment of patients with IgA nephropathy: evaluation of the safety and efficacy of Mycophenolate Mofetil. Curr Pharm Des. 2024;30(30):2400\u201309. https:\/\/doi.org\/10.2174\/0113816128304327240620093048.","journal-title":"Curr Pharm Des"},{"key":"4848_CR51","doi-asserted-by":"publisher","first-page":"1545329","DOI":"10.3389\/fneph.2025.1545329","volume":"5","author":"EJ Filippone","year":"2025","unstructured":"Filippone EJ, Gulati R, Farber JL. The road ahead: emerging therapies for primary IgA nephropathy. Front Nephrol. 2025;5:1545329. https:\/\/doi.org\/10.3389\/fneph.2025.1545329.","journal-title":"Front Nephrol"},{"issue":"5","key":"4848_CR52","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.smim.2006.04.006","volume":"18","author":"C Bossen","year":"2006","unstructured":"Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol. 2006;18(5):263\u201375. https:\/\/doi.org\/10.1016\/j.smim.2006.04.006.","journal-title":"Semin Immunol"},{"issue":"2","key":"4848_CR53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/nep.14130","volume":"28","author":"EYM Chung","year":"2023","unstructured":"Chung EYM, Badve SV, Heerspink HJL, et al. Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond? Nephrol (Carlton). 2023;28(2):97\u2013108. https:\/\/doi.org\/10.1111\/nep.14130.","journal-title":"Nephrol (Carlton)"},{"issue":"2","key":"4848_CR54","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.amjms.2020.10.003","volume":"361","author":"A Rajasekaran","year":"2021","unstructured":"Rajasekaran A, Julian BA, Rizk DV. IgA nephropathy: an interesting autoimmune kidney disease. Am J Med Sci. 2021;361(2):176\u201394. https:\/\/doi.org\/10.1016\/j.amjms.2020.10.003.","journal-title":"Am J Med Sci"},{"issue":"11","key":"4848_CR55","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s11255-019-02255-6","volume":"51","author":"J Yi","year":"2019","unstructured":"Yi J, He Z, Xu S, et al. Efficacy and safety of leflunomide in IgA nephropathy: a systematic review and meta-analysis. Int Urol Nephrol. 2019;51(11):1987\u201398. https:\/\/doi.org\/10.1007\/s11255-019-02255-6.","journal-title":"Int Urol Nephrol"},{"key":"4848_CR56","unstructured":"Garabed Eknoyan M, Norbert Lameire M. 2024."},{"key":"4848_CR57","doi-asserted-by":"publisher","first-page":"926517","DOI":"10.3389\/fimmu.2022.926517","volume":"13","author":"J Liao","year":"2022","unstructured":"Liao J, Zhou Y, Xu X, et al. Current knowledge of targeted-release budesonide in immunoglobulin A nephropathy: a comprehensive review. Front Immunol. 2022;13:926517. https:\/\/doi.org\/10.3389\/fimmu.2022.926517.","journal-title":"Front Immunol"},{"key":"4848_CR58","doi-asserted-by":"publisher","unstructured":"Knoppova B, Reily C, King RG, et al. Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment. J Clin Med. 2021.10(19). https:\/\/doi.org\/10.3390\/jcm10194501.","DOI":"10.3390\/jcm10194501"},{"key":"4848_CR59","doi-asserted-by":"publisher","unstructured":"Prattichizzo F, de Candia P, Ceriello A. Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists. Metabolism. 2021;120:154799. https:\/\/doi.org\/10.1016\/j.metabol.2021.154799.","DOI":"10.1016\/j.metabol.2021.154799"},{"key":"4848_CR60","doi-asserted-by":"publisher","unstructured":"Lee B, Holstein-Rathlou NH, Sosnovtseva O, et al. Renoprotective effects of GLP-1 receptor agonists and SGLT-2 inhibitors-is hemodynamics the key point?. Am J Physiol Cell Physiol. 2023;325(1):C243\u2013c256. https:\/\/doi.org\/10.1152\/ajpcell.00147.2023.","DOI":"10.1152\/ajpcell.00147.2023"},{"key":"4848_CR61","doi-asserted-by":"publisher","unstructured":"Rovin BH, Barratt J, Cook HT, et al. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4s):S1\u2013s71. https:\/\/doi.org\/10.1016\/j.kint.2025.04.004.","DOI":"10.1016\/j.kint.2025.04.004"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-026-04848-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04848-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-026-04848-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:23:06Z","timestamp":1776903786000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12882-026-04848-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4848"],"URL":"https:\/\/doi.org\/10.1186\/s12882-026-04848-7","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"255"}}